Medpace Holdings DCF valuation and fair value (MEDP)
Review Medpace Holdings's current market price, analyst target and financial fundamentals before building a discounted cash flow valuation.
Key company data
- Latest recorded price: $591.29 on 2026-09-04
- Market capitalization: $16.50B
- Price-to-earnings ratio: 34.72
- Analyst target price: $581.83
- Sector: Life Sciences Tools & Services
About Medpace Holdings
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Data last updated: